Potential Psychiatric Uses for MDMA

Introduction

The paper reviews evidence and regulatory considerations for 3,4-methylenedioxymethamphetamine (MDMA) used as an adjunct to psychotherapy. Background material summarises that MDMA-assisted psychotherapy typically involves two to three single supervised drug sessions spaced about a month apart, embedded within preparatory and integration psychotherapy. Earlier clinical work includes case reports and phase II randomised controlled trials (RCTs) that have reported initial safety and efficacy signals for treatment of post-traumatic stress disorder (PTSD), but MDMA remains a Schedule 1 controlled substance in the United States, creating substantial regulatory complexity. Yazar-Klosinski and colleagues set out to synthesise clinical, mechanistic, and regulatory information to frame potential psychiatric indications for MDMA-assisted psychotherapy and to consider pathways for moving from phase II results to definitive phase III testing and possible approval. The paper emphasises the single-dose, medication-assisted psychotherapy model as distinct from chronic daily pharmacotherapy and considers implications for toxicology testing, trial design, and implementation if efficacy is confirmed.